I am of the view that the company must do a licence deal on ‘something’ over the next 12 months to provide the company with sufficient cash to take one of the blockbusters to the finish line … without another domestic backed capital raise.
The only exception to that would be if the share price was much higher and they did a targeted ‘cross over’ equity funding deal as the precursor to a NASDAQ listing in 12 months.
we don’t want to be sitting here in 12 months worried about another discounted (highly dilutive) fund raising … and who knows what global equity markets are going to look like with Trump in the drivers seat!
Ann: Fourth Drug Program Progressing to Human Trials, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.36 |
Change
-0.005(0.37%) |
Mkt cap ! $790.3M | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.40 | $1.29 | $688.4K | 519.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 733 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 29100 | 3 |
View Market Depth
| Last trade - 16.10pm 17/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |